IL-23 p19 drugs for Psoriatic Arthritis
3 tracked IL-23 p19 drugs in the Psoriatic Arthritis race. The class explanation lives on the IL-23 p19 page; the full indication pipeline across every mechanism is on the Psoriatic Arthritis page.
3 approved / phase 4
Head-to-head evidence: guselkumab vs risankizumab · guselkumab vs tildrakizumab · risankizumab vs tildrakizumab